Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics

Spero Therapeutics, Inc. (SPRO): $1.64

0.07 (-4.09%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

B

Add SPRO to Watchlist
Sign Up

SPRO Price/Volume Stats

Current price $1.64 52-week high $2.00
Prev. close $1.71 52-week low $0.99
Day low $1.62 Volume 338,200
Day high $1.71 Avg. volume 303,389
50-day MA $1.63 Dividend yield N/A
200-day MA $1.40 Market Cap 88.35M

SPRO Stock Price Chart Interactive Chart >


Spero Therapeutics, Inc. (SPRO) Company Bio


Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.


SPRO Latest News Stream


Event/Time News Detail
Loading, please wait...

SPRO Latest Social Stream


Loading social stream, please wait...

View Full SPRO Social Stream

Latest SPRO News From Around the Web

Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript November 13, 2023 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $-0.15. Ted Jenkins: Thank you, operator, and thank you all for participating in today’s conference call. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the third […]

Yahoo | November 14, 2023

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR

Yahoo | November 13, 2023

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide

Yahoo | November 6, 2023

Spero Therapeutics to Present at Upcoming November Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at

Yahoo | November 1, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations.CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of

Yahoo | November 1, 2023

Read More 'SPRO' Stories Here

SPRO Price Returns

1-mo -5.75%
3-mo 13.10%
6-mo 43.86%
1-year -4.65%
3-year -87.56%
5-year -86.58%
YTD 11.56%
2023 -15.03%
2022 -89.19%
2021 -17.43%
2020 101.66%
2019 56.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!